Schering-Plough fertility drug aces Phase III

Schering-Plough's corifollitropin alfa--a fertility drug--met its primary endpoints in a Phase III non-inferiority trial. Corifollitropin alfa is a sustained follicle stimulant and was tested in 1509 patients. The ongoing pregnancy rate, the primary endpoint of the trial, obtained in the 150 mcg corifollitropin alfa treatment arm (38.9 percent per started cycle) was similar to that achieved in patients receiving 200 IU recombinant FSH (follitropin beta) (38.1 percent per started cycle). The results were presented at the European Society of Human Reproduction and Embryology conference.

- see the release for more

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.